Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CHINA PHARMA HOLDINGS, INC. (CPHI)

China Pharma to issue 12.6 million restricted shares for $6.93 million patent transfer

Neutral Impact 3 of 5 product/contract Written later

On February 26, 2026, subsidiary Hainan Helpson Medical & Biotechnology agreed to acquire the ownership of an invention patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang. The $6.93 million transfer price will be paid in company common stock at $0.55 per share, meaning the company is to issue 12,600,000 restricted shares that are not registered under the Securities Act.

Key points

  • Agreement dated February 26, 2026, between subsidiary Helpson and Xiaoyan Zhang, a technology transfer covering an invention patent for sublingual tablets
  • Transfer price of $6.93 million, paid in common stock at $0.55 per share
  • Company to issue an aggregate of 12,600,000 restricted shares, offered under the Regulation S exemption to a non-U.S. person in an offshore transaction
  • Transferor or a designated third party will provide technical services, including product research and development and registration support

The filing

CompanyCHINA PHARMA HOLDINGS, INC. (CPHI)
Form8-K, current report
Filed with the SECMar 3, 2026, 4:05 PM ET
Accession number0001213900-26-023022

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.